Abstract
Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent workoutlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming doseof the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequentialquizartinib primed injections offluorouracil (5-FU), we demonstrated a novel and effective strategy toeliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).
Original language | English |
---|---|
Article number | e1378156 |
Journal | Molecular & Cellular Oncology |
Volume | 4 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2 Nov 2017 |